Cell Therapy · Hematopoietic Cellular Therapy
Hematopoietic cellular therapy research.
Hematopoietic cellular therapy research at the preclinical stage requires donor-traceable HSC-bearing material with full identity documentation. ExoBioCorp supplies UCB-NNC and CD34-enriched preparations qualified for in-vitro research and animal-model studies.
Research applications we supply
- HSC engraftment method development in animal models
- HSC expansion media and cytokine cocktail optimization
- Colony-forming-unit (CFU) assays
- Single-cell transplant studies for serial-self-renewal verification
- Donor-source comparative HSC pharmacology
- Pre-engraftment conditioning regimen research
Products typically supplied
- Altogex™ UCB-NNC — full nucleated cell fraction including hematopoietic progenitors
- Nexa-BMCD34-SD — CD34+ enriched bone marrow cells
- Nexa-HBMMSC-1M — supporting MSC for stromal co-culture
- Nexa-LEUKO-SER variants — leukocyte serum for expansion media development
Documentation provided
- Per-lot Certificate of Analysis with viability and identity panel
- CD34+ percentage by flow cytometry
- Donor identifier and donor eligibility documentation reference
- Cold-chain temperature log
- Cryopreservation protocol and recommended thaw recovery procedure